Page 3 - பயோகான் உயிரியல் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Biocon Biologics and Serum Institute Life Sciences announce Strategic Alliance
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Biocon Biologics 15% stake Serum Institute Life Sciences valuation USD 4 9 bn
indiatvnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatvnews.com Daily Mail and Mail on Sunday newspapers.
Biocon Biologics posts 53% growth in revenues at ₹664 crore for Q4FY21
April 29, 2021
For the full year, revenues have grown 21 per cent to ₹2,800 crore
Revenues of Biocon Biologics Limited, a subsidiary of Biocon Limited, grew by 53 per cent year-on-year (y-o-y) at ₹664 crore for fourth quarter of financial year 2021-22, mainly driven by emerging markets business. Q4FY21 EBITDA stood at ₹164 crore and EBITDA margin was 25 per cent.
Commenting on company’s performance, Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd, said, “We have reported a revenue growth of 53 per cent y-o-y at ₹664 crore for Q4FY21, led by a strong growth of our emerging markets business, supported by market share gains for Pegfilgrastim and Trastuzumab biosimilars in the developed markets, and contributions from Insulin Glargine introduced in the US earlier this fiscal. The marketing authorisation approvals for our biosimilar insulin Aspart and biosimilar Bevacizumab in the EU au
ISPE announces its manufacturing Facility of the Year Awards winners
SHARES
The awardees, including Takeda, Janssen and Gilead, are recognised for their state-of-the-art facility design, construction and operation projects.
The International Society for Pharmaceutical Engineering (ISPE) has announced 2021’s Facility of the Year Awards (FOYA) winners. The award programme, established in 2004, recognises state-of-the-art facility design, construction and operation projects utilising innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines and demonstrate advances in project delivery.
Categories and awardees
International AG for its NINLARO
® The Grange Castle Factory P2 Facility in Grange Castle, Ireland. The facility includes drug substance manufacture, drug product blistering and secondary packaging, QA testing and QC operations in one dedicated building. It was designed to keep things small, simple, safe and integrated
Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
Posted On: 2021-03-01 02:55:59 (Time Zone: Arizona, USA)
Biocon Biologics Ltd., a fully integrated pure play biosimilars company and a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that Mr Shreehas Tambe has been promoted to the position of Deputy Chief Executive Officer of Biocon Biologics Limited w.e.f. March 1, 2021.
A Biocon veteran, Shreehas joined Biocon in 1997 and has, since then, taken on positions of increasing responsibility. He has over 20 years of leadership experience in operational and strategic roles and has led large, diverse teams at R&D, Manufacturing and Projects & Engineering during his tenure. Shreehas began his professional journey at Biocon as a Management Trainee starting out in the R&D department, where he led the design and development of a novel bioreactor, the PlaFractor™, a unique solid state bioreactor that got Biocon its first U.S. pat
vimarsana © 2020. All Rights Reserved.